Distribution of Anti-Tax Reactivity by the Level of Anti–HTLV-I Titer Among Cases, Controls, and All HTLV-I Carriers in the Study Cohort
| Anti–HTLV-I Titer . | No. of Anti-Tax Positive Subjects (%) . | ||
|---|---|---|---|
| Case (N = 5) . | Control (N = 38) . | Study Cohort3-150 (N = 306) . | |
| 4,096 ≤ titer | 0/2 (0%) | 5/6 (83%) | 49/59 (83%) |
| 1,024 ≤ titer ≤ 2,048 | 1/1 (100%) | 7/8 (88%) | 52/77 (68%) |
| 128 ≤ titer ≤ 512 | 2/2 (100%) | 8/17 (47%) | 68/134 (51%) |
| 16 ≤ titer ≤ 64 | 0/0 (UD) | 2/7 (29%) | 12/36 (33%) |
| Anti–HTLV-I Titer . | No. of Anti-Tax Positive Subjects (%) . | ||
|---|---|---|---|
| Case (N = 5) . | Control (N = 38) . | Study Cohort3-150 (N = 306) . | |
| 4,096 ≤ titer | 0/2 (0%) | 5/6 (83%) | 49/59 (83%) |
| 1,024 ≤ titer ≤ 2,048 | 1/1 (100%) | 7/8 (88%) | 52/77 (68%) |
| 128 ≤ titer ≤ 512 | 2/2 (100%) | 8/17 (47%) | 68/134 (51%) |
| 16 ≤ titer ≤ 64 | 0/0 (UD) | 2/7 (29%) | 12/36 (33%) |
For cases and controls, cross-classification was by the observation of viral markers at the first screen at which data were available for the index case.
Abbreviation: UD, undefined.
Includes all HTLV-I–positive cohort subjects whose anti-Tax reactivity was available.